Sonorous Neurovascular Receives FDA IDE Approval for First U.S. Pivotal Trial of a Venous Sinus Stent to Treat Pulsatile Tinnitus

B-SILENT 2 adds a U.S. pivotal study to the company's international clinical program and advances its cerebral venous disease platform LAKE FOREST, Calif., Oct. 7, 2026 /PRNewswire/ -- Sonorous Neurovascular, a clinical-stage medical device company developing purpose-built therapies for...

Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.